focus -WSS

focus

author：fashion 2025-09-30 13:13:52 - browse：66

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Peter Hotez and the public health issue of online harassment
Next article： New lawsuit accuses health insurer Cigna of denying claims in bulk

focus

WSS

Will the FTC rein in IQVIA's health data empire?

7 people shot in DC, police say

The haunting brain science of long Covid

New Alzheimer's drugs heat up race for early detection blood tests

4th of July breaks record for highest global temperature ever measured

Community addresses injustice for Long Island mothers

hotspot

focus

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

UHS says company favors patients whose insurance pays more

Alkermes shareholders re

UHS says company favors patients whose insurance pays more

Duchenne breakthrough therapy leaves behind pioneering families

Did the public have the right to know Arthur Ashe had AIDS?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

PhRMA sues HHS over Medicare drug price negotiation

Novavax promises a turnaround & Lilly roils the obesity market

Did the public have the right to know Arthur Ashe had AIDS?

entertainment

7 people shot in DC, police say

Did the public have the right to know Arthur Ashe had AIDS?

Biden warns of ‘dark winter’ during final presidental debate

Dems pitch expanding Medicare power to negotiate drug prices

Doctor appointment wait times are getting worse

Roche’s Alnylam deal shows drug firms interested in heart drugs

hotspot

focus

focus

focus